Peripheral Vascular Disorders
Conference Coverage
Benefit of rivaroxaban after limb revascularization greatest in those with comorbid CAD
New results from the landmark VOYAGER PAD trial identify which patients benefit most from adding rivaroxaban after limb revascularization.
Conference Coverage
Polygenic risk score helps target AAA screening
Researchers validated a 29-item genetic risk score that improved abdominal aortic aneurysm screening pick-up when added to sex and age.
Conference Coverage
PCSK9 inhibitors unexpectedly link with lower VTE, aortic stenosis
Conference Coverage
VOYAGER PAD: Clopidogrel adds no benefit to rivaroxaban plus aspirin after PAD interventions
Analysis of VOYAGER PAD results showed no benefit with clopidogrel, but patients on three antithrombotics had more bleeding episodes.
Conference Coverage
CARAVAGGIO expands DOAC pool in cancer-related VTE
Conference Coverage
Larger absolute rivaroxaban benefit in diabetes: COMPASS
Conference Coverage
Rivaroxaban plus aspirin safely benefits PAD patients after limb revascularization
From the Journals
More conflicting evidence on paclitaxel devices in PAD
Use of paclitaxel-coated devices for treating PAD has been riddled with conflicting findings. Two new studies further deepen the debate.
From the Journals
First-time marathon runners rewind the clock on vascular aging
Marathon training took about 4 years off vascular age as measured by aortic stiffness.
Conference Coverage
Geriatric Nutritional Risk Index predicts long-term outcomes in PAD
PARIS –
Conference Coverage
Isolated iliac disease a marker for better health status?
CHICAGO – Trial shows patients with isolated iliac and multilevel disease do better after intervention than those with other types of PAD.